Predictive factors of durability to sitagliptin: Slower reduction of glycated hemoglobin, older age and higher baseline glycated hemoglobin (Q33628631)

28 July 2017

Predictive factors of durability to sitagliptin: Slower reduction of glycated hemoglobin, older age and higher baseline glycated hemoglobin (English)

1 reference

28 July 2017

1 reference

glycated hemoglobin

23 October 2023

2

Sunghwan Suh

1 reference

28 July 2017

Hye Soo Chung

1

1 reference

28 July 2017

Mi Yeon Kim

3

1 reference

28 July 2017

Soo Kyoung Kim

4

1 reference

28 July 2017

Hee Kyung Kim

5

1 reference

28 July 2017

Ji In Lee

6

1 reference

28 July 2017

Kyu Yeon Hur

7

1 reference

28 July 2017

Jae Hyeon Kim

8

1 reference

28 July 2017

Yong-Ki Min

9

1 reference

28 July 2017

Myung-Shik Lee

10

1 reference

28 July 2017

Kwang-Won Kim

11

1 reference

28 July 2017

Sun Wook Kim

12

1 reference

28 July 2017

Jae Hoon Chung

13

1 reference

28 July 2017

Moon-Kyu Lee

14

1 reference

28 July 2017

2 September 2013

1 reference

Journal of Diabetes Investigation

28 July 2017

1 reference

28 July 2017

5

1 reference

28 July 2017

1

1 reference

28 July 2017

51-59

1 reference

DPP-4 inhibitors: what may be the clinical differentiators?

28 July 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4025229

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4025229

beta-cell failure in diabetes and preservation by clinical treatment

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4025229

Dipeptidyl peptidase-IV inhibitors: a major new class of oral antidiabetic drug

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4025229

The place of sulfonylureas in the therapy for type 2 diabetes mellitus

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4025229

Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4025229

Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4025229

Metformin effects on dipeptidylpeptidase IV degradation of glucagon-like peptide-1.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4025229

Oral antihyperglycemic therapy for type 2 diabetes: scientific review

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4025229

Randomized, controlled trials, observational studies, and the hierarchy of research designs

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4025229

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4025229

Diet and oral antidiabetic drugs and plasma sugar and insulin levels in patients with maturity-onset diabetes mellitus.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4025229

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.

14 July 2018

1 reference

Enhanced secretion of glucagon-like peptide 1 by biguanide compounds

21 January 2018

1 reference

Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes.

21 January 2018

1 reference

Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes

21 January 2018

1 reference

SUIT, secretory units of islets in transplantation: An index for therapeutic management of islet transplanted patients and its application to type 2 diabetes.

21 January 2018

1 reference

Secretory unit of islet in transplantation (SUIT) and engrafted islet rate (EIR) indexes are useful for evaluating single islet transplantation.

21 January 2018

1 reference

Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes

21 January 2018

1 reference

Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea

21 January 2018

1 reference

Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial.

21 January 2018

1 reference

Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes

21 January 2018

1 reference

Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes

21 January 2018

1 reference

Factors predicting therapeutic efficacy of combination treatment with sitagliptin and metformin in type 2 diabetic patients: the COSMETIC study.

21 January 2018

1 reference

Effects of chronic administration of alogliptin on the development of diabetes and β-cell function in high fat diet/streptozotocin diabetic mice.

21 January 2018

1 reference

Selective β-Cell Loss and α-Cell Expansion in Patients with Type 2 Diabetes Mellitus in Korea

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4025229

Sitagliptin add-on to low dosage sulphonylureas: efficacy and safety of combination therapy on glycaemic control and insulin secretion capacity in type 2 diabetes

30 October 2018

1 reference

Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes

21 January 2018

1 reference

Effect of Single Oral Doses of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Incretin and Plasma Glucose Levels after an Oral Glucose Tolerance Test in Patients with Type 2 Diabetes

21 January 2018

1 reference

Dipeptidyl peptidase-4 inhibitors and HbA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials

21 January 2018

1 reference

Contributing factors related to efficacy of the dipeptidyl peptidase-4 inhibitor sitagliptin in Japanese patients with type 2 diabetes

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24843737

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

The safety, efficacy and predictors for HbA1c reduction of sitagliptin in the treatment of Japanese type 2 diabetes

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24843737

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1111/JDI.12127

1 reference

28 July 2017

1 reference

28 July 2017

1 reference